Physiologically Based Pharmacokinetic Modelling to Predict Pharmacokinetics of Enavogliflozin, a Sodium-Dependent Glucose Transporter 2 Inhibitor, in Humans

Physiologically Based Pharmacokinetic Modelling to Predict Pharmacokinetics of Enavogliflozin, a Sodium-Dependent Glucose Transporter 2 Inhibitor, in Humans

Enavogliflozin is a sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor approved for clinical use in South Korea. As SGLT2 inhibitors are a treatment option for patients with diabetes, enavogliflozin is expected to be prescribed in various populations. Physiologically based pharmacokinetic (P...

Full description

Bibliographic Details
Main Authors: Min-Soo Kim, Yoo-Kyung Song, Ji-Soo Choi, Hye Young Ji, Eunsuk Yang, Joon Seok Park, Hyung Sik Kim, Min-Joo Kim, In-Kyung Cho, Suk-Jae Chung, Yoon-Jee Chae, Kyeong-Ryoon Lee
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Pharmaceutics
Subjects:
enavogliflozin
DWP16001
GCC5694A
sodium-glucose cotransporter 2 inhibitor
diabetes mellitus
physiologically based pharmacokinetic modelling
Online Access:https://www.mdpi.com/1999-4923/15/3/942

Internet

https://www.mdpi.com/1999-4923/15/3/942

Similar Items